Thyroxine Replacement Therapy After Lobectomy for Low-risk Papillary Thyroid Carcinoma

PHASE2RecruitingINTERVENTIONAL

Enrollment

140

Participants

Timeline

Start Date

August 1, 2022

Primary Completion Date

July 31, 2026

Study Completion Date

December 31, 2026

Conditions

Thyroid CancerSurgeryRecurrence

Interventions

DRUG

Thyroxine

The treatment goal after lobectomy was to control TSH within the normal reference range (0.4-5 mU/L)

Trial Locations (1)

RECRUITING

Cancer Hospital, Chinese Academy of Medical Science, Beijing

All Listed Sponsors

lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER